IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F328/2025.3

Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family in GtoPdb v.2025.3

Chloe J. Peach[1]

1. University of Nottingham, UK

Abstract

The TAM receptor family, named from the first letter of each of its constituents, respond to growth arrest specific protein 6 and protein S. These ligands are secreted plasma proteins which undergo vitamin K-dependent post-translational modifications generating carboxyglutamate-rich domains which are able to bind to negatively-charged surfaces of apoptotic cells. Members of this RTK family represented a novel structural motif, when originally sequenced.

Contents

This is a citation summary for Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [7].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=328
Introduction to Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=328

Receptors

- Axl(AXL receptor tyrosine kinase)
  https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835
- Tyro3(TYRO3 protein tyrosine kinase)
  https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1836
- Mer(MER proto-oncogene, tyrosine kinase)
  https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1837

References

1. Akalu YT, Rothlin CV and Ghosh S. (2017) TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. *Immunol Rev* **276**: 165-177 [PMID:28258690]
2. Anastassiadis T, Deacon SW, Devarajan K, Ma H and Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1039-45 [PMID:22037377]

3. Bae SH, Kim JH, Park TH, Lee K, Lee BI and Jang H. (2022) BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity. *Exp Mol Med* **54**: 1450-1460 [PMID:36056187]
4. Baladi T, Abet V and Piguel S. (2015) State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. *Eur J Med Chem* **105**: 220-37 [PMID:26498569]
5. Bannen LC, Bui M, Jiang F, Tso K, Wang Y and Xu W. (2019) Compounds for the treatment of kinase-dependent disorders Patent number: WO2019148044A1. Assignee: Exelixis, Inc.. Priority date: 26/01/2018. Publication date: 01/08/2019.
6. Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL and Cohen PL. (2003) The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. *Eur J Immunol* **33**: 2160-7 [PMID:12884290]
7. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
8. Caberoy NB, Alvarado G, Bigcas JL and Li W. (2012) Galectin-3 is a new MerTK-specific eat-me signal. *J Cell Physiol* **227**: 401-7 [PMID:21792939]
9. Caberoy NB, Zhou Y and Li W. (2010) Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. *EMBO J* **29**: 3898-910 [PMID:20978472]
10. Chan PY, Carrera Silva EA, De Kouchkovsky D, Joannas LD, Hao L, Hu D, Huntsman S, Eng C, Licona-Limón P and Weinstein JS *et al.*. (2016) The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity. *Science* **352**: 99-103 [PMID:27034374]
11. Chan S, Zhang Y, Wang J, Yu Q, Peng X, Zou J, Zhou L, Tan L, Duan Y and Zhou Y *et al.*. (2022) Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors *Journal of Nedicinal Chemistry*
12. Cochran JR, Goaccia AJ, Miao Y, Kariolis M, Kapur S and Mathews II. (2015) High-affinity binding to gas6 Patent number: WO2015030849. Assignee: The Board Of Trustees Of The Leland Stanford Junior University. Priority date: 30/08/2013. Publication date: 05/03/2015.
13. Cruz-López O, Temps C, Longo B, Myers SH, Franco-Montalban F and Unciti-Broceta A. (2019) Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. *ACS Omega* **4**: 21620-21626 [PMID:31867559]
14. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1046-51 [PMID:22037378]
15. Davra V, Kimani SG, Calianese D and Birge RB. (2016) Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. *Cancers (Basel)* **8** [PMID:27916840]
16. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R and Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. *Biochem J* **451**: 313-28 [PMID:23398362]
17. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG and Gordonov S *et al.*. (2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* **13**: 1118-28 [PMID:23023392]
18. Han J, Bae J, Choi CY, Choi SP, Kang HS, Jo EK, Park J, Lee YS, Moon HS and Park CG *et al.*. (2016) Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice. *Autophagy* **12**: 2326-2343 [PMID:27780404]
19. Heiring C, Dahlbäck B and Muller YA. (2004) Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family. *J Biol Chem* **279**: 6952-8 [PMID:14623883]
20. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J and Heckrodt TJ *et al.*. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. *Cancer Res* **70**: 1544-54 [PMID:20145120]
21. Huang X, Finerty P, Walker JR, Butler-Cole C, Vedadi M, Schapira M, Parker SA, Turk BE, Thompson DA and Dhe-Paganon S. (2009) Structural insights into the inhibited states of the Mer receptor tyrosine kinase. *J Struct Biol* **165**: 88-96 [PMID:19028587]
22. Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones 2nd DS, Kapur S, Mathews II and Koong AC *et al.*. (2017) Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. *J Clin Invest* **127**: 183-198 [PMID:27893463]
23. Kong D, Tian Q, Chen Z, Zheng H, Stashko MA, Yan D, Earp HS, Frye SV, DeRyckere D and Kireev D *et al.*. (2024) Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors. *J Med Chem* **67**: 5866-5882 [PMID:38556760]
24. Lee HK, Kim HW, Lee IY, Lee J, Lee J, Jung DS, Lee SY, Park SH, Hwang H and Choi JS *et al.*. (2014) G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. *Blood* **123**: 2209-19 [PMID:24532805]

25. Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D and Levis M. (2017) Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. *Blood* **129**: 257-260 [PMID:27908881]
26. Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA and Chen H *et al.*. (2012) The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. *J Med Chem* **55**: 6523-40 [PMID:22734674]
27. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z and Lin G *et al.*. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. *J Med Chem* **61**: 11398-11414 [PMID:30480444]
28. Lu Q and Lemke G. (2001) Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. *Science* **293**: 306-11 [PMID:11452127]
29. Miles DH, Lamani M, Paladugu SR, Qu S, Foley CN, Sharif EU, Thomas J, Nareddy P, Beatty JW and Gal B *et al.*. (2025) Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy. *J Med Chem* **68**: 10663-10676 [PMID:40407274]
30. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H and Bearss DJ. (2011) Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. *ACS Med Chem Lett* **2**: 907-912 [PMID:22247788]
31. Moody G, Belmontes B, Masterman S, Wang W, King C, Murawsky C, Tsuruda T, Liu S, Radinsky R and Beltran PJ. (2016) Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo. *Int J Cancer* **139**: 1340-9 [PMID:27170265]
32. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H and Mizuno K. (1996) Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. *J Biol Chem* **271**: 30022-7 [PMID:8939948]
33. Nam K, Kim J, Park D, Jeon Y, Yang YI and Kang HK. (2021) Quinoline derivatives as inhibitors of axl/mer rtk and csf1r Patent number: US20210163448A1. Assignee: QURIENT CO Ltd. Priority date: 31/05/2019. Publication date: 03/06/2021.
34. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G and Hatch H *et al.*. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. *Cancer Res* **70**: 1524-33 [PMID:20145145]
35. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F and Fededa JP *et al.*. (2014) The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. *Nature* **507**: 508-12 [PMID:24553136]
36. Paolino M and Penninger JM. (2016) The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. *Cancers (Basel)* **8** [PMID:27775650]
37. Patwardhan PP, Ivy KS, Musi E, de Stanchina E and Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. *Oncotarget* **7**: 4093-109 [PMID:26675259]
38. Peng YH, Li MC, Yen WC, Yeh TK, Hsueh CC, Kuo FM, Lai YL, Chang L, Lee LC and Chen PY *et al.*. (2025) Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix. *J Med Chem* **68**: 10877-10896 [PMID:40391976]
39. Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J and Perrin LA *et al.*. (2013) Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. *Bioorg Med Chem Lett* **23**: 1051-5 [PMID:23312943]
40. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T and Wan X *et al.*. (2019) Discovery of N^1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N^3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. *Eur J Med Chem* **163**: 10-27 [PMID:30503936]
41. Rothlin CV, Carrera-Silva EA, Bosurgi L and Ghosh S. (2015) TAM receptor signaling in immune homeostasis. *Annu Rev Immunol* **33**: 355-91 [PMID:25594431]
42. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB and Lemke G. (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell* **131**: 1124-36 [PMID:18083102]
43. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, Timpl R and Hohenester E. (2006) Structural basis for Gas6-Axl signalling. *EMBO J* **25**: 80-7 [PMID:16362042]
44. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A and Henley B *et al.*. (2009) Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. *J Med Chem* **52**: 1251-4 [PMID:19260711]
45. Shao WH, Zhen Y, Eisenberg RA and Cohen PL. (2009) The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. *Clin Immunol* **133**: 138-44 [PMID:19631584]

46. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR and Jones PF. (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. *Cell* **80**: 661-70 [PMID:7867073]
47. Sun X, Wang L, Yang H and Hu H. (2020) Crystal forms of compound, preparation method therefor, pharmaceutical composition and application thereof Patent number: WO2020216188. Assignee: Beijing Kangchen Pharmaceutical Co., Ltd.. Priority date: 20/04/2020. Publication date: 29/10/2020.
48. Wallet MA, Sen P, Flores RR, Wang Y, Yi Z, Huang Y, Mathews CE, Earp HS, Matsushima G and Wang B *et al.*. (2008) MerTK is required for apoptotic cell-induced T cell tolerance. *J Exp Med* **205**: 219-32 [PMID:18195070]
49. Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T, Wu P, Xie S, Bian W and Zhang C *et al.*. (2021) AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Res* **31**: 126-140 [PMID:33420426]
50. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC and Zarrinkar PP *et al.*. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. *Chem Biol* **17**: 1241-9 [PMID:21095574]
51. Xi N. (2015) Substituted quinoline compounds and methods of use Patent number: US9133162B2. Assignee: Sunshine Lake Pharma Co Ltd, Calitor Sciences LLC. Priority date: 28/02/2011. Publication date: 15/09/2015.
52. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW and Manro JR *et al.*. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. *Invest New Drugs* **31**: 833-44 [PMID:23275061]
53. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT and McDonald DM. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. *Cancer Res* **71**: 4758-68 [PMID:21613405]
54. Yu Y, Jang M, Miyashiro J, Clark RF, Zhu GD, Gong J, Dai Y, Frey RR, Penning TD and Kim H *et al.*. (2024) Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor. *J Med Chem* **67**: 17000-17032 [PMID:39283694]
55. Zhang Z. (2015) Aminopyridine derivatives as tam family kinase inhibitors Patent number: WO2015081257A2. Assignee: Signalchem Lifesciences Corporation. Priority date: 26/11/2014. Publication date: 04/06/2015.
56. Zhao J, Zhang D, Zhang W, Stashko MA, DeRyckere D, Vasileiadi E, Parker RE, Hunter D, Liu Q and Zhang Y *et al.*. (2018) Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. *J Med Chem* **61**: 10242-10254 [PMID:30347155]